Popular drugs double Pfizer's profit Pfizer Inc.'s profit more than doubled in the second quarter, reflecting growth in international pharmaceutical sales, the drug giant said Wednesday.Profit increased to $2.8 billion, up 119 percent from $1.3 billion a year earlier, the...
Popular drugs double Pfizer's profit Pfizer Inc.'s profit more than doubled in the second quarter, reflecting growth in international pharmaceutical sales, the drug giant said Wednesday.Profit increased to $2.8 billion, up 119 percent from $1.3 billion a year earlier, the...
Pfizer Reports Second-Quarter 2008 Results Pfizer Reaffirms Full-Year 2008 Revenue and Adjusted Diluted EPS(1) Guidance; On-Track to Achieve Total Cost-Reduction Target Second-Quarter 2008 Revenues of $12.1 Billion Compared with $11.1 Billion in the Year-Ago Quarter Second-Quarter...
Pfizer Reports Second-Quarter 2008 Results -- Pfizer Reaffirms Full-Year 2008 Revenue and Adjusted Diluted EPS(1) Guidance; On-Track to Achieve Total Cost-Reduction Target -- Second-Quarter 2008 Revenues of $12.1 Billion Compared with $11.1 Billion in the Year-Ago Quarter -- Second...
Pfizer Q2 profit doubles on international sales, lower costs; reiterates FY08 outlook - Update 2 drug manufacturer Pfizer Inc.(PFE | Quote | Chart | News | PowerRating) reported a profit for the second quarter that more than doubled, helped by lower restructuring charges and double-digit international revenue growth.
On an adjusted...
Pfizer Beats EPS Target by a Penny Pfizer PFE posted greater-than-expected profit and revenue for the second quarter Wednesday.Foreign exchange rates helped to balance a highly competitive statin market, loss of some product exclusivity and safety concerns that marred U.S....
Pfizer Reports Second-Quarter 2008 Results - Pfizer Inc (NYSE: PFE): -0- See end of text prior to tables for notes.Pfizer Inc (NYSE: PFE) today reported financial results for the second-quarter 2008.
The Company recorded revenues of $12.1 billion, an increase of 9% compared with...
Pfizer Beats EPS Target by a Penny Pfizer PFE Shares of the Big Pharma company added 49 cents, or 2.7%, to $18.84 in recent early morning trading Wednesday.Pfizer said it earned 41 cents a share in the recent quarter, vs.
18 cents a share in the comparable year-ago...
Pfizer Reports Second-Quarter 2008 Results c (NYSE: PFE): ($ in millions, except per share amounts) Second-Quarter Year-to-Date ------------------------ ------------------------ 2008 2007 Change 2008 2007 Change -------- -------- ------ -------- -------- ------ Reported Revenues $ 12...
Pfizer Reports Second-Quarter 2008 Results ($ in millions, except per share amounts) Second-Quarter Year-to-Date ------------------------ ------------------------ 2008 2007 Change 2008 2007 Change -------- -------- ------ -------- -------- ------ Reported Revenues $ 12,129 $ 11,084 9...
Pfizer Reports Second-Quarter 2008 Results - Pfizer Inc (NYSE: PFE): -0- ($ in millions, except per share amounts) Second-Quarter Year-to-Date ------------------------ ------------------------ -------- -------- ------ -------- -------- ------ Reported Revenues $ 12,129 $ 11,084 9% $...
Pfizer Reports Second-Quarter 2008 Results - Pfizer Inc (NYSE: PFE): -0- ($ in millions, except per share amounts) Second-Quarter Year-to-Date ------------------------ ------------------------ -------- -------- ------ -------- -------- ------ Reported Revenues $ 12,129 $ 11,084 9% $...
Pfizer Reports Second-Quarter 2008 Results Pfizer Inc (NYSE: PFE): -0- *T ($ in millions, except per share amounts) Second-Quarter Year-to-Date ------------------------ ------------------------ 2008 2007 Change 2008 2007 Change -------- -------- ------ -------- -------- ------...
Old Schizophrenia Drug Fights Violence as Effectively as Second-Generation Antipsychotics DURHAM, N.C., July 1 -- The newer, atypical antipsychotics were no better than a first-generation agent in reducing violent behavior in schizophrenic patients, researchers here said.Among 1,445 patients randomly assigned to one of five...
Live From Bio: Personalized Medicine Fool contributor and health-care sector editor Brian Orelli hung out at the Bio International Convention this week.This concludes his series on the hot topics at the conference that will affect the industry and the stocks you invest in.
Live From Bio: Personalized Medicine Fool contributor and health-care sector editor Brian Orelli hung out at the Bio International Convention this week.This concludes his series on the hot topics at the conference that will affect the industry and the stocks you invest in.
FDA warns schizophrenia drugs pose fatal risk to some seniors WASHINGTON (AP) - The government is warning doctors that prescribing a certain group of psychiatric drugs to seniors suffering from dementia can increase their risk of death.Anti-psychotic drugs are approved to treat schizophrenia and...
FDA warns schizophrenia drugs pose fatal risk to some seniors FDA warns schizophrenia drugs pose fatal risk to some seniors Last Update: 6:45 pm (/File) WASHINGTON (AP) - The government is warning doctors that prescribing a certain group of psychiatric drugs to seniors suffering from dementia can...
FDA warns schizophrenia drugs pose fatal risk to some seniors Conventional Antipsychotic Drugs Atypical Antipsychotics Compazine (prochlorperazine) Abilify (aripiprazole) Haldol (haloperidol) Clozaril (clozapine) Loxitane (loxapine) FazaClo (clozapine) Mellaril (thioridazine) Geodon (ziprasidone)...
Monthly Shot Treats Schizophrenia (Washington) -- A new, once-a-month shot shows promise for the treatment of schizophrenia.The new drug is called paliperidone palmitate.
It's an injectable form of the second-generation, or 'atypical,' antipsychotic medication Invega.
